Global Neurostimulation Devices Market Outlook
Revenue, 2024
$5.6B
Forecast, 2034
$16.0B
CAGR, 2025 - 2034
11.1%
The Neurostimulation Devices industry revenue is expected to be around $6.2 billion in 2025 and expected to showcase growth with 11.1% CAGR between 2025 and 2034. Neurostimulation devices, designed to deliver electrical impulses to specific nerve targets, play a critical role in managing chronic pain and neurological conditions such as Parkinson's disease, epilepsy, and depression. In 2024, the neurostimulation device market was valued at approximately USD 5.6 billion, with projections to reach USD 10.5 billion by 2030 and potentially USD 17.8 billion by 2035, growing at a CAGR of 11.1%. This growth is attributed to increasing incidences of neurological disorders and advancements in non-invasive neurostimulation technologies.
Neurostimulation devices have proven effective in enhancing patients’ quality of life by alleviating chronic pain and managing symptoms of debilitating conditions. With rising healthcare awareness and ongoing innovations, these devices are becoming integral to neurological and pain management therapies
Market Key Insights
- The Neurostimulation Devices market is projected to grow from $5.6 billion in 2024 to $16.0 billion in 2034. This represents a CAGR of 11.1%, reflecting rising demand across Pain Management, Epilepsy and Parkinson's Disease.
- Abbott (St. Jude Medical), Medtronic, Boston Scientific Corporation are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Neurostimulation Devices market and are expected to observe the growth CAGR of 8.1% to 11.7% between 2024 and 2030.
- Emerging markets including India, Brazil and South Korea are expected to observe highest growth with CAGR ranging between 10.7% to 13.9%.
- Transition like Shift Toward Wearable Neurostimulation Solutions is expected to add $575 million to the Neurostimulation Devices market growth by 2030.
- The Neurostimulation Devices market is set to add $10.4 billion between 2024 and 2034, with manufacturer targeting Chronic Pain & Migraine Application projected to gain a larger market share.
- With Increasing prevalence of neurological disorders, and Growth in chronic pain management applications, Neurostimulation Devices market to expand 187% between 2024 and 2034.
Opportunities in the Neurostimulation Devices
Emerging healthcare markets present significant growth opportunities for neurostimulation device adoption, particularly in pain management
Growth Opportunities in North America and Europe
North America leads in neurostimulation device demand, supported by a high incidence of neurological disorders and advanced healthcare infrastructure. Key players like Medtronic and Boston Scientific are prominent in this region
Europe, particularly Germany and the United Kingdom, shows growing adoption of neurostimulation devices in chronic pain and neurological care. Companies such as Abbott and Nevro Corp lead in this market
Market Dynamics and Supply Chain
01
Driver: Increasing Prevalence of Neurological Disorders, and Technological Advancements in Non-Invasive Neurostimulation
Rising cases of conditions like Parkinson's and epilepsy drive demand for neurostimulation devices in managing symptoms Developments in non-invasive devices enhance patient comfort and expand applications, boosting the adoption of neurostimulation therapy
With chronic pain affecting millions globally, neurostimulation devices provide an effective solution, especially in cases where traditional treatments are also inadequate
02
Restraint: High Costs of Neurostimulation Devices, and Complex Regulatory Approvals
The high cost of devices and surgical implantation limits accessibility, particularly in low-income regions
Stringent regulations and lengthy approval processes impact the availability of neurostimulation devices
03
Opportunity: Increased Applications in Mental Health Disorders and Development of Miniaturized and Wearable Devices
As research into neurostimulation’s impact on mental health advances, new applications in treating depression and anxiety present a growth area
Advances in miniaturization and wearable neurostimulation devices enable broader usage in home care and outpatient settings
04
Challenge: Risk of Device Malfunction or Infection
As with any implantable device, there are risks of malfunction or infection, which can limit patient adoption and trust in neurostimulation therapy
Supply Chain Landscape
1
Raw Material Supplier
3MDuPont
2
Device Manufacturer / Assembler
MedtronicBoston Scientific
3
Distributor
McKessonCardinal Health
4
End-User
HospitalsClinicsHome Care
1
Raw Material Supplier
3MDuPont
2
Device Manufacturer / Assembler
MedtronicBoston Scientific
3
Distributor
McKessonCardinal Health
4
End-User
HospitalsClinicsHome Care
Use Cases of Neurostimulation Devices in Pain Management & Epilepsy
Pain Management : Neurostimulation devices, particularly spinal cord stimulators, are extensively used for chronic pain relief, improving patient outcomes in conditions such as back pain and sciatica. Leading providers include Boston Scientific and Nevro Corp
Parkinson's Disease : Deep brain stimulators help control symptoms of Parkinson's disease, such as tremors, by targeting specific brain areas. Companies like Medtronic and Abbott specialize in this segment
Epilepsy : Vagus nerve stimulators reduce seizure frequency in epilepsy patients, offering a non-invasive alternative to manage epilepsy. Key providers include LivaNova and Cyberonics
Depression : Transcranial magnetic stimulation devices are used to manage depression symptoms, especially in treatment-resistant cases, with companies like NeuroStar and BrainsWay leading this application
Recent Developments
Recent advancements in neurostimulation devices focus on wearable and miniaturized solutions. Boston Scientific’s wearable device supports pain management in outpatient care, Medtronic expands Parkinson’s solutions, and LivaNova enhances seizure control in epilepsy
October 2024 : Boston Scientific launched a wearable neurostimulation device for chronic pain, targeting outpatient care
July 2024 : Medtronic expanded its deep brain stimulation offerings with an enhanced system for Parkinson’s treatment
March 2024 : LivaNova introduced a new vagus nerve stimulator designed to improve seizure control in epilepsy patients
Impact of Industry Transitions on the Neurostimulation Devices Market
As a core segment of the Medical Device industry,
the Neurostimulation Devices market develops in line with broader industry shifts.
Over recent years, transitions such as Shift Toward Wearable Neurostimulation Solutions and Advancements in Device Miniaturization have redefined priorities
across the Medical Device sector,
influencing how the Neurostimulation Devices market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift Toward Wearable Neurostimulation Solutions
Wearable devices make neurostimulation therapy more accessible and convenient, especially for patients in outpatient care This industry transition is expected to add $575 million in the industry revenue between 2024 and 2030.
02
Advancements in Device Miniaturization
New miniaturized devices improve patient comfort and expand the applications of neurostimulation in various therapeutic areas